Choroidal thickness changes determined by SS OCT following intravitreal bevacizumab

Purpose To report choroidal thickness (CT) changes using a SS OCT prototype following intravitreal bevacizumab injections. Methods Seventeen patients were treated by one single intravitreal 1.25 mg injection of bevacizumab (IVB). The macular area was examined using an SS‐OCT prototype system based on swept‐source OCT and was used to image the full‐thickness choroid and sclera. A CT profile of the macula was created by manually measuring CT (from the posterior edge of retinal pigment epithelium to the choroid/sclera junction) subfoveally, and three further determinations were performed every 750 μm temporal and nasal to the fovea. CT was determined immediately before and 24 hours after performing 1.25 mg IVB. Results Seventeen eyes from 17 patients (11 eyes with exudative age related macular degeneration, 4 eyes with retinal vein occlusion, 1 eye with myopic choroidal neovascularization, and 1 eye with diabetic macular edema) were examined. Nine patients were male and 8 were female. Mean age was 73 ± 11years range 53 to 88. Pearson correlation coefficient among observers averaged 0.90 (range 0.54 to 0.99). Changes in choroidal thickness were not significant for any of the determinations (Student t test for paired data). Changes in central foveal thickness were almost statistically significant (Student t test for paired data). Conclusion Our findings suggest that one single IVB does not seem to induce acute choroidal thinning.